相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study
Elahe A. Mostaghel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors
Yue Wu et al.
PROSTATE (2013)
The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific
Rishi Raj Chhipa et al.
PROSTATE (2013)
Quality of life issues in men undergoing androgen deprivation therapy: a review
Rowan G. Casey et al.
ASIAN JOURNAL OF ANDROLOGY (2012)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
Eleni Efstathiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
Masuo Yamaoka et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2012)
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Juanita M. Crook et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
Tomohiro Kaku et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer
James L. Mohler et al.
CANCER RESEARCH (2011)
Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone
James L. Mohler et al.
CLINICAL CANCER RESEARCH (2011)
SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
Ming Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Kai-Hsiung Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years
Peter Iversen et al.
BJU INTERNATIONAL (2010)
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
Per-Anders Abrahamsson
EUROPEAN UROLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer
Yu-Ning Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Individualizing Quality-of-Life Outcomes Reporting: How Localized Prostate Cancer Treatments Affect Patients With Different Levels of Baseline Urinary, Bowel, and Sexual Function
Ronald C. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
Prateek Mendiratta et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
Jennifer A. Locke et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2009)
Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation Therapy
Satyan K. Shah et al.
JOURNAL OF UROLOGY (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
Jennifer A. Locke et al.
CANCER RESEARCH (2008)
Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study
Yoichi Arai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
Tadas Vasaitis et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Quality of life and satisfaction with outcome among prostate-cancer survivors
Martin G. Sanda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions
Anthony V. D'Amico et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
Elahe A. Mostaghel et al.
CANCER RESEARCH (2007)
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline
D. Andrew Loblaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
Jeanny B. Aragon-Ching et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
Edward M. Messing et al.
LANCET ONCOLOGY (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer
MT Salam et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2005)
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of Phase III RTOG 85-31
MV Pilepich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
CG Drake et al.
CANCER CELL (2005)
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor
RV Clark et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model
VD Handratta et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
P Bader et al.
JOURNAL OF UROLOGY (2003)
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02
GE Hanks et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M Bolla et al.
LANCET (2002)
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
M Mercader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
K Tomera et al.
JOURNAL OF UROLOGY (2001)
Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients
RL Leibowitz et al.
ONCOLOGIST (2001)
分享论文
